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mproving the
utcomes of Heart Failure Care*
utting Technology Second
dward P. Havranek, MD, FACC
enver, Colorado
eart failure mortality has declined during the past 20 years
1,2), largely as a result of advances in drug treatment. By
nd large, treatment has been based on the concept that
iminishing the neurohormonal activation caused by heart
ailure prevents long-term deterioration in cardiac function.
hus, patients with heart failure now routinely take beta-
lockers, angiotensin-converting enzyme inhibitors or an-
iotensin receptor blockers, and spironolactone. Recently,
owever, new treatments based on the neurohormonal concept
ave failed to show any benefit (3–5), leading some to call for
ew concepts to guide the treatment of heart failure.
At first glance, disease management would not appear to
e a leading candidate as one of these new guiding concepts.
t is not based on new insights into the biology of heart
ailure and, indeed, is not a new concept at all. Yet evidence
ontinues to emerge that reorganizing the delivery of care to
atients with heart failure may have the impact on outcomes
hat new drug treatments have not had.
See page 1654
Disease management, also more descriptively referred to
s multidisciplinary chronic care management, has been
efined as “a system of coordinated health care interventions
nd communications for populations with conditions in
hich patient self-care efforts are significant. [It] supports
he physician or practitioner/patient relationship and plan of
are, emphasizes prevention of exacerbations and complica-
ions utilizing evidence-based practice guidelines and pa-
ient empowerment strategies, and evaluates clinical, hu-
anistic, and economic outcomes on an ongoing basis with
he goal of improving overall health” (6). When imple-
ented as thusly defined, disease management aligns well
ith the prescription for the American health care system
ssued by the Institute of Medicine. Cooperation among
linicians, anticipation of needs, evidence-based decision-
aking, and the patient as the source of control are among
he 10 rules for the redesign of health care processes in its
eport entitled “Crossing the Quality Chasm” (7).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.w
From the Denver Health Medical Center, and the University of Colorado Health
ciences Center, Denver, Colorado.We have a wealth of data on the effectiveness of disease
anagement for patients with heart failure. Three recent
eta-analyses of randomized studies concluded that, de-
pite considerable heterogeneity in the structure of the
rograms studied, disease-management programs reduce
ospital admission rates (8–10). The largest randomized trial
eported to date demonstrated a significant reduction in mor-
ality for the intervention group (11). Several other smaller
tudies have also reported mortality reductions (12–14).
In this issue of the Journal, Cleland et al. (15) report results
rom a randomized trial of a uniquely structured disease-
anagement program from 12 hospitals in Germany, the
etherlands, and the United Kingdom. The intervention
hey tested consisted of monthly telephone contact with a
urse, augmented by daily transmission of information on
atients’ weight, blood pressure, and cardiac rhythm over
hone lines using innovative technology. The study was
igorously conducted and analyzed and contained compar-
sons both to usual care and to nurse contact without the
ddition of the telemonitoring technology. The sample size
as calculated using an ambitious 40% estimate of benefit
rom telemonitoring on the primary end point. The study
as terminated early because patients in the control arm had
tatistically higher mortality than patients in the disease-
anagement arms and because benefit was statistically
nlikely for the telemonitoring arm. The results were
urable over a median of 484 days of follow-up. This
elatively long follow-up period is important in light of the
ndings of the Specialized Primary and Networked Care in
eart Failure (SPAN-CHF) trial (16), in which the bene-
ts of disease management attenuated after three months of
ollow-up. Despite the fact that the null hypothesis for the
tudy was accepted, this study decidedly should not be
iewed as having negative results.
As pointed out by the authors, providers had no experi-
nce with the technology before their study participation.
atients showed a remarkable willingness to use the tech-
ology, with 81% of patients transmitting more than 80% of
ata daily despite their relatively advanced age and heart
ailure severity. As already noted, the sample size for the
tudy was relatively modest. On the basis of these factors
lone, I agree with the authors that the results of the study
upport further research into this novel approach. Questions
or future analysis include whether health status and health-
elated quality-of-life measures more sensitive than New
ork Heart Association functional class might be affected,
hether there is heterogeneity among sites with respect to the
mpact of the technology, and whether the cost of the tech-
ology compares favorably to other heart failure treatments.
Patients in the telemonitoring arm had a greater number
f hospitalizations, which implies that the increased surveil-
ance resulted in a greater tendency to admit patients with
ubclinical illness and that perhaps these anticipatory ad-
issions did not affect outcome. The fact that hospital stays
ere shorter in the telemonitoring arm is a small comfort,
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Editorial Comment May 17, 2005:1665–6iven that the first days of a hospital stay are associated with
igher costs than subsequent days (17). Better admission
riteria or better alternatives to admission for telemonitored
atients should be sought.
This study extends the results of the previous studies that
emonstrated reductions in mortality with multidisciplinary
hronic care management for heart failure and of studies
hat made use of regular telephone contact with patients.
he greatest challenge we now face is not how best to
esign disease-management programs but how to surmount
he barriers to implementing them. Successes with disease-
anagement programs are not universal, emphasizing the
act that programs must be evaluated for effectiveness on an
ngoing basis after their implementation. The definition of
ffectiveness should encompass health status and mortality
s well as financial end points. Payers should be evaluating
ommercial disease-management services that have been
dded onto usual sources of care against this broad defini-
ion of effectiveness. As others have pointed out, the health
are system in the U.S. is not well organized to deliver care
or chronic illness (18,19). In general, providers of ambula-
ory care, acute care, and long-term care are organizationally
eparated. No financial incentives exist to deliver integrated
are; indeed, the incentives may be perverse (20). Payers,
articularly Medicare, should move forcefully in the direc-
ion of encouraging integrated care. Professional organiza-
ions should take forceful roles in encouraging policy change
nd in ensuring that policy changes keep patient outcomes
head of cost reduction.
Finally, this study reinforces what we should have known
ll along. The greatest gains demonstrated in this study
ame when patients had regular contact with a well-trained
urse; if any additional gains associated with the addition of
elemonitoring were present, they were too small to detect.
he heart of the practice of medicine is a relationship
etween a provider and a patient with the patient as the
ocal point. When we create systems that encourage patients
o have strong relationships with well-equipped providers
nd when these relationships promote involvement of pa-
ients in the treatment of their illnesses, health improves.
his study helps us understand that new technologies
hould be viewed as useful adjuncts and not as the center-
ieces of redesigned health care systems. Novel applications
f technology almost certainly have a role in improving the
utcomes of patients with heart failure. Technology, how-
ver, should come second; the patient-centered relationship
etween patient and provider comes first.
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